Compare iShares MSCI Singapore ETF (EWS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Novartis AG — how do they compare? iShares MSCI Singapore ETF trades at $33.69, while Novartis AG trades at $153.01 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| EWS | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $33.92 | $168.62 |
52-Week Low | $26.71 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $33.68, up 1.54% today and near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though oscillators signal overbought conditions. The ETF benefits from Singapore's economic resilience, AI-driven growth prospects, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026 (SEC filing, 2026-08-05).
Outlook is positive due to Singapore's market reforms and AI infrastructure investments, but risks include concentrated financial sector exposure and regional economic volatility. The bullish technical setup and institutional accumulation support upside potential, though overbought RSI levels warrant caution for near-term entries.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
